Tyro Payments Limited Overview
Tyro Payments is Australia's largest independent, domestically focused merchant acquirer and the only payments specialist in the market that also holds a full banking licence. It processes roughly A$44bn a year for about 77,800 merchants, concentrated in small and medium-sized enterprises across hospitality, retail, services and — its standout vertical — healthcare, where Tyro Health integrates Medicare, private-health-fund and pet-insurance claiming with payments. Its competitive identity rests on deep point-of-sale (POS) integration (580+ integrations), a proprietary low-cost acquiring platform, and bundling of payments with a business transaction account, term deposits, cash-flow loans and, since the Thriday acquisition, accounting software. After years of loss-making growth and two failed take-private attempts, the business has been re-engineered into a profitable, cash-generative operator with a ~29% EBITDA margin on gross profit. Its strategic challenge is converting low-single-digit volume growth into faster top-line expansion against the big four banks and global platforms such as Square, Stripe and Adyen.
Company's own description
In its standard boilerplate (FY26 results release, 25 Aug 2026), Tyro describes its founding purpose as making payments the easiest part of doing business, and states that it serves more than 77,800 Australian merchants with in-store, online and on-the-go payment solutions, supported by over 580 integrations across hospitality, retail, services and health, together with integrated banking, lending and accounting. Older ASX boilerplate (2022) characterised Tyro as a technology-focused, values-driven group and as Australia's fifth-largest merchant acquiring bank by terminals, behind the four major banks (Source: Tyro ASX release, 18 Oct 2022; Listcorp company description).
What the company does
Tyro is a merchant acquirer: it contracts with merchants to accept card payments (Visa, Mastercard, eftpos, American Express acceptance, UnionPay/Alipay historically), routes and settles those transactions through its own switching and acquiring platform, and charges a merchant service fee (MSF). Its margin is the MSF less interchange (paid to card issuers) and scheme fees (paid to networks), plus terminal rental and ancillary fees. Because Tyro is itself an ADI, it can settle merchant funds into its own Tyro transaction accounts (often same-day/instantly), take deposits and lend.
Business model and revenue mix
| Revenue stream | Nature | Model classification | Commentary |
|---|---|---|---|
| Merchant service fees (MSF) on card transactions | Ad valorem % of TTV or blended pricing | Usage-based "service" revenue | Dominant revenue driver; payments gross profit was A$195.0m of A$220.1m total in FY25 (~89%) (FY25 results release) |
| Terminal rental and accessory sales | Monthly rental per terminal; some hardware sales | Subscription / product | Bundled with MSF; not separately disclosed |
| Tyro Health claiming/transaction fees | Per-claim/transaction fees from practitioners and funders | Usage-based / platform | Part of Payments segment |
| Banking — net interest margin on deposits and loans | Interest income on unsecured cash-flow loans; low-cost merchant deposits | Financial services | Banking GP A$13.4m in FY25 (FY25 release) |
| Corporate — interest on Tyro's own cash and investments | Treasury income | Other | Corporate GP A$11.7m in FY25 (FY25 release) |
| Accounting/financial-management software (Thriday → "Tyro Accounting") | Subscription | SaaS | New from FY26; size not disclosed |
Tyro's economics are almost entirely transaction-based and recurring:
There is no material licensing revenue. Revenue is effectively 100% Australian.
Value-chain position
Tyro sits at the acquirer/processor layer, between merchants (and their POS/practice-management software vendors) and the card schemes and issuing banks. It is vertically integrated across: terminal fleet management (terminals manufactured by third parties — the 2021 outage was linked to Worldline terminal software), switching, acquiring, settlement, and banking. It does not issue consumer cards. Distribution runs through direct sales, POS/software partners (integrations are its moat), ISO partners and, historically, the Bendigo Bank alliance channel.
Customer types and end-markets
SMEs: across hospitality (cafés, restaurants, pubs, clubs), retail, services and trades, automotive, mobile businesses, not-for-profits (tyro.com industry navigation).
Healthcare practitioners: GPs, specialists, dentists, allied health, veterinary (Tyro Health: A$7.9bn TTV in FY26; Allied Health +26%, Dental +19%) (FY26 release).
Enterprise and franchise: newer focus; FY26 wins included Bakers Delight, Lune and Drummond Golf (FY26 release).
eCommerce merchants: eCommerce volumes +25% in FY26 (FY26 release).
Independent characterisation
Tyro is best understood as a scale-constrained, high-quality niche acquirer that has pivoted from a "growth at all costs" fintech to a "profitable compounder" narrative. Its real moats are (1) integration depth in verticals where generic terminals perform poorly (health claiming, hospitality POS with pay-at-table/split bills), and (2) a banking licence that lets it monetise merchant float and lend against card flows. Its weaknesses are a concentrated domestic SME base exposed to discretionary spending, structurally slow TTV growth since FY23 (0.8%, 0.2%, 2.9% in FY24–FY26), and price competition from banks that bundle acquiring with lending, and from global platforms with vastly greater R&D budgets. The business is now as much about gross-profit-per-merchant expansion (banking attach, health, software) as about volume.
Strategy
Stated strategy (FY26 Annual Report / Investor Presentation themes — paraphrased)
-
"Executing the next phase of growth in a $1 trillion payments market" — investment focused on four priority growth opportunities: Health, Banking, Enterprise and eCommerce (FY26 investor presentation).
-
Deepen SME relationships, win more enterprise and franchise customers — sales teams realigned to where Tyro has the "strongest right to win" (FY26 release; presentation).
Payments + banking + software: the integrated proposition: payments as the core, banking and accounting as differentiators that raise customer value and lower churn (H1 FY26 release; FY26 presentation).
Australian home-market advantage: speed, responsiveness, local support and tailored products vs global providers (FY26 release).
Financial discipline and operating leverage: CEO describes Tyro's infrastructure as one of the cheapest in the market, so incremental merchants carry low marginal cost (Proactive interview, Sept 2026).
Inorganic optionality: balance sheet and cash give capacity for organic or inorganic growth (H1 FY26 release); board continues to assess M&A (2025 AGM chair).
Strategic initiatives (last 24 months)
| Initiative | Timing | Description | Status | Source |
|---|---|---|---|---|
| New banking platform (Tyro Transaction Account) | Pilot FY25; launch to new merchants Sept 2025; H1 FY26 formal launch | Replatformed business banking with faster settlement | Live; transaction accounts +38% in H1 FY26; banking accounts +35% FY26 | FY25 and H1 FY26 releases |
| Tyro Flexi Loan | H1 FY26 | New cash-flow loan product | Live; originations +19.4% FY26 | H1 FY26 release |
| Omnichannel payments upgrades | FY25 | Tyro Pro Key, Embedded Payments, Payment Links, Tyro BYO on Android | Live | FY25 release |
| Health product refresh | 2,026 | Tyro Health Pro and Pro Lite; GapOnly for vets | Live | FY26 slides; July 2026 media release |
| Enterprise/franchise push | FY26 | Wins: Bakers Delight, Lune, Drummond Golf | Ongoing | FY26 release |
| Thriday acquisition → Tyro Accounting | Announced Dec 2025; completed FY26 | Adds accounting/tax/invoicing | Integrating | FY26 release; Finovate |
| Odoo partnership | Jul 2025 | ERP/POS payments integration | Live | MarketScreener |
| RBA reform readiness | 2,026 | Removing surcharging functionality; repricing for interchange cuts; marketing "no-surcharge" simplicity | Effective 1 Oct 2026 | FY26 call; tyro.com blog |
| Smartpay merger attempt | Mar–Apr 2025 | Synergistic cash-and-scrip bid | Abandoned | Business News Australia |
| Leadership renewal | Nov 2025–Feb 2026 | New CEO, COO; CEO joins board | Complete; CFO search open | ASX releases |
Cost programmes
Tyro has not announced a named cost-out programme with a dollar target in the period. Cost discipline is evidenced by: FY25 operating costs down 2.2% (Capital Brief); H1 FY26 operating expenses down 2.9% (H1 FY26 call highlights); operating efficiency (opex/GP) improved from 92% in FY22 to 69% in FY25 (2025 AGM).
Guidance and medium-term targets
| Guidance item | FY24 guidance | FY25 guidance | FY26 guidance | FY27 guidance |
|---|---|---|---|---|
| Normalised gross profit low end (AUD M) | 206 | 218 | 230 | 240 |
| Normalised gross profit high end (AUD M) | 215 | 226 | 240 | 255 |
| Actual normalised gross profit (AUD M) | 210.8 | 220.1 | 231.8 | — |
| EBITDA margin guidance low (%) | — | 28 | 28.5 | 28.5 |
| EBITDA margin guidance high (%) | — | 28 | 30.0 | 30.5 |
| Actual EBITDA margin (%) | 26.4 | 28.0 | 28.9 | — |
Sources: FY23 release (FY24 guidance A$206–215m GP, EBITDA A$52–58m); FY24 release (FY25 guidance A$218–226m, ~28%); FY25 release (FY26 A$230–240m, 28.5–30%); FY26 release (FY27 A$240–255m, 28.5–30.5%). FY27 guidance midpoint implies ~6.8% GP growth and EBITDA of ~A$70–78m. Tyro has delivered within its GP guidance range for three consecutive years (FY24–FY26), though FY24 TTV guidance (A$45–47.5bn) was missed (actual A$42.9bn). No formal medium-term (3–5 year) numeric targets are published; the 2025 AGM presentation referenced "medium-term value drivers" (GP growth and EBITDA margin) without published numbers.
Products & Services
Payments segment
| Product | Description / capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Tyro Pro (Pro series EFTPOS terminals) | Android-based countertop/portable terminals; integrated EFTPOS, pay@table, split bills, discreet tipping, custom welcome screen, Tap & Save | SMEs, hospitality, retail | Tyro Pro rolled out FY22; FY24 annual report references Tyro Pro updates | Monthly rental + MSF (simple, blended or cost-plus plans); exact rates on tyro.com merchant-fees page |
| Tyro Pro Key | New terminal variant launched FY25 (keypad form factor) | SMEs needing PIN-pad style device | FY25 | Rental + MSF |
| Tyro Go | Mobile Bluetooth card reader/dongle | Micro and mobile businesses | FY22 | Hardware purchase + MSF |
| Tap to Pay / Tyro BYO app | Accept contactless payments on iPhone or Android phone without a terminal | Mobile, micro merchants | iPhone earlier; Android launched FY25 | MSF only |
| Integrated EFTPOS / POS integrations | 580+ integrations with POS and practice-management systems via Tyro SDK and Tyro Connect | Merchants using POS/PMS software | Ongoing; 34 new direct POS integrations in FY25 | Bundled |
| Tyro Connect | Integration hub linking apps (ordering, delivery, loyalty) with POS for hospitality | Cafés, QSRs, pubs, clubs | Launched c.FY21 | — |
| Embedded Payments | SDK to embed Tyro acceptance inside third-party software platforms | ISVs/software partners | FY25 | Revenue share / MSF |
| Online payments (eCommerce gateway) | Card-not-present acceptance for websites | Omnichannel merchants | Ongoing; eCommerce volumes +25% FY26 | MSF |
| Payment Links | Send payment requests by link/SMS/email | Services, trades, health | FY25 | MSF |
| Tyro App / Merchant Portal | Reporting, settlement, account management | All merchants | Ongoing | Free |
| Odoo integration | Payment integration with Odoo ERP/POS | SMEs on Odoo | Announced July 2025 | — |
Tyro Health (within Payments)
| Product | Description | Target | Launch | Pricing |
|---|---|---|---|---|
| Tyro Health (ex-Medipass) platform | Digital claiming and payments connecting payers (Medicare, private health funds, insurers), providers and patients | Medical, dental, allied health practices | Medipass acquired 2021; Tyro Health unit FY22 | Per-transaction/claim fees + MSF |
| Tyro Health Pro (EFTPOS) | Health-optimised terminal supporting claims, gap payments, split transactions | Allied health and dental | Launched 2026 | Rental + fees |
| Tyro Health Pro Lite | Lighter health terminal variant | Smaller practices | FY26 | — |
| Tyro Health Online | Online/telehealth claiming and payments | Practices with online bookings | Referenced in FY26 presentation | — |
| GapOnly® (veterinary) | Pet-insurance claims and payments so owners pay only the gap at the clinic | Veterinary clinics | Media release 22 July 2026 | — |
| PMS integrations | Integration into ~125 practice management systems | Health practices | Cited Sept 2026 | Bundled |
Sources: FY26 release; Investing.com FY26 slides summary; tyro.com media list; Proactive interview with CEO (Sept 2026).
Banking segment
| Product | Description | Target | Launch | Pricing |
|---|---|---|---|---|
| Tyro Transaction Account (new banking platform) | Business transaction account with fast settlement of card takings; replaced legacy Tyro Bank Account | Tyro merchants | Piloted FY25, launched to new merchants Sept 2025; formally launched H1 FY26 | Fee-free / interest features (details on tyro.com) |
| Term Deposits | Business term deposits | Merchants with surplus cash | Long-standing | Interest rate offered |
| Business Loans / Tyro Flexi Loan | Unsecured cash-flow loans underwritten against card takings and repaid from settlement | Merchants with ≥ established card volumes | Lending since FY16; Flexi Loan launched H1 FY26 | Fixed fee/interest; FY26 cashback offer |
Banking KPIs: banking accounts +35% (FY26), deposits +27%, loan originations +19.4%; 34% of new merchants chose to bank with Tyro in June 2026 (FY26 release; FY26 slides).
Accounting / financial management
| Product | Description | Target | Launch | Pricing |
|---|---|---|---|---|
| Tyro Accounting (Thriday platform) | AI-powered integrated banking, bookkeeping, tax and invoicing "financial operating system" for small businesses | Sole traders, micro and small businesses | Thriday acquired Dec 2025/Jan 2026; Tyro Accounting launched FY26 | Subscription |
Financial Narrative
Income statement
Sources: FY22 results release (29 Aug 2022); FY23 results release and Appendix 4E (29–31 Aug 2023); FY24 release and Appendix 4E (26 Aug 2024); FY25 release (26 Aug 2025); FY26 release and Appendix 4E (25 Aug 2026); revenue FY24 from Business News Australia; FY25/FY26 normalised revenue from FY26 Appendix 4E (via Kalkine); FCF FY25 from Capital Brief. Operating income (EBIT) is not presented consistently by Tyro and is not publicly disclosed in the materials reviewed. FY26 EPS derived, not company-stated.
Source conflicts flagged:
-
FY26 NPAT: Kalkine (citing Appendix 4E) reports statutory NPAT attributable of A$21.319m (+19.7%); Capital Brief reported "net profit after tax A$24.72m", which matches normalised PBT — Capital Brief appears to have mislabelled normalised PBT.
-
FY25 revenue: A$486.1m (normalised, per FY26 Appendix 4E) vs A$487.3m (Capital Brief).
-
FY22 normalised gross profit: A$148.5m per FY23 release; the FY22 release reported payments normalised GP of A$141.5m and group statutory GP of A$154.7m.
Growth rates:
CAGRs: Normalised gross profit FY22→FY26 CAGR ≈ 11.8% (148.5→231.8); FY23→FY26 ≈ 6.3%. Management cites a 14% three-year GP CAGR and ~79–80% three-year EBITDA CAGR to FY25 (FY25 results release/transcript). TTV FY22→FY26 CAGR ≈ 6.7%, but only ≈1.3% FY23→FY26. Revenue CAGR (FY24→FY26, company-reported) ≈ 1.9%.
Commentary — income statement. The five-year record divides into two eras. FY22–FY23 was a volume-led recovery: post-COVID reopening, the Bendigo Alliance's first full year (A$5.2bn TTV in FY22) and inflation lifted TTV 34% then 25%. FY23 was the inflection to profitability, as gross profit rose 30% while operating costs grew far more slowly, taking EBITDA from A$10.7m to A$42.3m. From FY24 onward volumes stalled (TTV growth 0.2%–2.9%) as cost-of-living pressure hit discretionary SME spend and churn rose. Gross profit nonetheless kept growing because of (a) the FY24 "pricing transformation" (repricing plans and passing through scheme costs), (b) banking growth, (c) higher corporate interest income, and (d) health-vertical expansion. Margin expansion since FY24 has been cost-driven: management stated that in FY22 operating expenses consumed 92% of gross profit, versus an operating-efficiency ratio of 69% in FY25 (2025 AGM CEO address). FY26 showed the first re-acceleration of core volume growth (Tyro Core payment volumes +4.4% vs 1.7% in FY25) and an EBITDA margin of 28.9%. The statutory NPAT dip in FY25 (A$17.8m vs A$25.7m) reflects FY24's benefit from tax and Bendigo commission-liability remeasurement effects rather than operating deterioration.
Half-year progression
Sources: H1 FY25 release (26 Feb 2025); H1 FY26 release (24 Feb 2026); H1 FY26 call highlights (FCF A$13.6m, +52%); H1 FY25 TTV derived from +4.0% growth. H1 FY25 FCF derived from the +52% growth figure. Implied H2 FY26 EBITDA was ≈A$27.4m (66.9 − 39.5), reflecting management's flagged H2 investment step-up.
Balance sheet
Tyro is an ADI: its balance sheet contains merchant deposits (liabilities) and merchant loans (assets), so industrial metrics such as "net debt" and "working capital" are of limited meaning.
Sources: FY24 and FY26 Appendix 4E (NTA and exclusions); FY23 Appendix 4E (NTA 0.01); Tyro ASX release 18 Oct 2022 (FY22 deposits/loans); FY23 AGM/release (FY23 deposits A$92.7m, originations A$149.7m).
Additional context: H1 FY26 "available funds" exceeded A$140m (H1 FY26 call highlights). Total debt (short/long split), net debt, goodwill separately, and working capital for each year: not publicly verified in this research. Tyro has no material corporate borrowings disclosed; its funding is merchant deposits and equity.
Implied net tangible assets FY26: ≈A$128m (A$0.24 × ~532m shares) — derived.
Cash flow
Sources: FY24 release (FY23 A$5.7m, FY24 A$30.4m); Capital Brief (FY25 A$19.6m); FY26 release (A$29.4m) and FY26 call (44% conversion). Operating cash flow and capex (including capitalised development) by year were not separately verified. No buybacks have been announced (no buyback authorisation found in ASX announcements reviewed).
Ratios
Derivations: GP/revenue uses company-reported revenue; GP per merchant uses ~76,000 (FY25) and ~77,800 (FY26) merchants.
Indicatively, using the stale Trading Economics equity figure (A$216.8m), FY26 statutory ROE would be ≈10% — treat as indicative only. Cash conversion cycle is not a meaningful metric for an acquirer/ADI. HALO lists ROIC of 11.7% (period unspecified).
Commentary — balance sheet and cash. Tyro's capital story is one of steady de-risking: NTA per share rose from A$0.01 (FY23) to A$0.24 (FY26) as intangibles (largely the Bendigo customer-relationship asset) amortise and retained losses are rebuilt by profits. The business is self-funding, pays no dividend, and holds surplus capital that management explicitly frames as optionality for organic and inorganic growth (H1 FY26 release). The FY25 FCF dip versus FY24 reflects timing, investment and tax effects rather than weaker earnings; FY26 FCF of A$29.4m (44% of EBITDA) re-established the FY24 level. With a market cap near A$357m, FY26 FCF implies a free-cash-flow yield of roughly 8% — a key element of the value case.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key products |
|---|---|---|
Payments | Card acquiring, terminal rental, eCommerce, Tyro Health claiming and payments, embedded payments | Tyro Pro series terminals, Tyro Go, Tap to Pay/BYO app, Payment Links, eCommerce gateway, Tyro Health Pro/Pro Lite, Tyro Health Online, GapOnly (vet), Embedded Payments SDK |
Banking | Merchant deposits and lending | Tyro Transaction Account, Term Deposits, Business Loans/Flexi Loan (cash-flow lending) |
Corporate (other) | Interest on Tyro's own cash/investments; group costs not allocated | — |
(New in FY26) Accounting | — | Tyro Accounting app/portal |
Segment gross profit (AUD Mn, normalised)
| Segment gross profit (AUD Mn, normalised) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Payments gross profit (AUD Mn) | 177.4 | 186.7 | 195.0 | — |
Banking gross profit (AUD Mn) | 9.7 | 12.6 | 13.4 | — |
Corporate gross profit (AUD Mn) | 6.0 | 11.5 | 11.7 | — |
Total gross profit (AUD Mn) | 193.2 | 210.8 | 220.1 | 231.8 |
Segment GP growth and mix
| Segment GP growth and mix | FY24 | FY25 |
|---|---|---|
Payments GP growth (%) | 5.2 | 4.4 |
Banking GP growth (%) | 29.4 | 6.7 |
Corporate GP growth (%) | 90.2 | 1.5 |
Payments share of total GP (%) | 88.6 | 88.6 |
Banking share of total GP (%) | 6.0 | 6.1 |
Corporate share of total GP (%) | 5.5 | 5.3 |
Segment revenue (AUD Mn; MarketScreener aggregate)
| Segment revenue (AUD Mn; MarketScreener aggregate) | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Payments revenue (AUD Mn) | 229 | 319 | 419 | 472 | 461 |
Banking revenue (AUD Mn) | 3.22 | 5.5 | 9.37 | 14.72 | 14.78 |
Corporate and other revenue (AUD Mn) | 6.08 | 1.79 | 11.19 | 11.48 | 11.66 |
Income Statement and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Total transaction value (AUD Bn) | 34.2 | 42.6 | 42.9 | 43.0 | 44.3 |
Revenue, company/press-reported (AUD Mn) | — | — | 471.4 | 486.1 | 489.4 |
Revenue, MarketScreener aggregate (AUD Mn) | 326 | 440 | 498 | 486 | — |
Gross profit, statutory group (AUD Mn) | 154.7 | 204.3 | — | — | — |
Gross profit, normalised (AUD Mn) | 148.5 | 193.2 | 210.8 | 220.1 | 231.8 |
EBITDA, normalised (AUD Mn) | 10.7 | 42.3 | 55.7 | 61.6 | 66.9 |
EBITDA margin on gross profit (%) | 7.2 | 21.9 | 26.4 | 28.0 | 28.9 |
Profit before tax, normalised (AUD Mn) | -16.1 | 4.5 | 19.5 | 17.7 | 24.7 |
Profit before tax, statutory (AUD Mn) | -29.6 | 2.5 | 22.4 | 17.8 | 22.3 |
Net profit after tax, statutory (AUD Mn) | -29.6 | 6.0 | 25.7 | 17.8 | 21.3 |
Basic EPS, statutory (AUD cents, derived ≈ NPAT / ~525–532m shares) | — | — | — | — | 4.0 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD Mn) | — | 5.7 | 30.4 | 19.6 | 29.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGrowth metric (%)
| Growth metric (%) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
TTV growth (%) | 24.6 | 0.8 | 0.2 | 2.9 |
Normalised gross profit growth (%) | 30.1 | 9.1 | 4.4 | 5.3 |
EBITDA growth (%) | 295.3 | 31.6 | 10.6 | 8.6 |
Revenue growth, company-reported (%) | — | 8.2 | 3.1 | 0.7 |
Income Statement and Margin Analysis (%) (Half-Yearly)
| Half-year metric | H1 FY25 | H1 FY26 |
|---|---|---|
Transaction value (AUD Bn) | 22.0 | 22.9 |
Normalised revenue (AUD Mn) | 248.3 | 251.1 |
Normalised gross profit (AUD Mn) | 112.0 | 117.6 |
EBITDA (AUD Mn) | 33.0 | 39.5 |
EBITDA margin on GP (%) | 29.5 | 33.6 |
Statutory profit before tax (AUD Mn) | 10.3 | 17.7 |
Free cash flow (AUD Mn) | 9.0 | 13.6 |
Per-Share Data and Key Financials
| Balance sheet metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Net tangible assets per share (AUD) | — | 0.01 | 0.13 | 0.19 | 0.24 |
Intangible assets excluded from NTA (AUD Mn) | — | — | 59.8 | — | 42.6 |
Right-of-use assets (AUD Mn) | — | — | 23.6 | — | 13.6 |
Deferred tax assets, gross (AUD Mn) | — | — | 20.4 | — | 19.1 |
Merchant deposits (AUD Mn) | 83.3 | 92.7 | — | — | — |
Loan originations in year (AUD Mn) | 99.1 | 149.7 | — | — | — |
Cash flow metric (AUD Mn)
| Cash flow metric (AUD Mn) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Free cash flow (AUD Mn) | — | 5.7 | 30.4 | 19.6 | 29.4 |
FCF conversion of EBITDA (%) | — | 13.5 | 54.6 | 31.8 | 44.0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Key Financials
| Ratio | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
EBITDA / gross profit (%) | 21.9 | 26.4 | 28.0 | 28.9 |
Normalised gross profit / revenue (%) | — | 44.7 | 45.3 | 47.4 |
Statutory NPAT / revenue (%) | — | 5.5 | 3.7 | 4.4 |
Gross profit per merchant (AUD K, derived) | — | — | 2.90 | 2.98 |
Revenue by Region and Revenue by Region (%)
| Region | FY23 | FY24 | FY25 |
|---|---|---|---|
Australia revenue (AUD Mn, MarketScreener aggregate) | 440 | 498 | 486 |
Australia share of revenue (%) | 100 | 100 | 100 |
Rest of world revenue (AUD Mn) | 0 | 0 | 0 |
Vertical / channel growth (%, FY26)
| Vertical / channel growth (%, FY26) | FY26 |
|---|---|
Allied Health TTV growth (%) | 26 |
Dental TTV growth (%) | 19 |
eCommerce volume growth (%) | 25 |
Banking accounts growth (%) | 35 |
Group TTV growth (%) | 2.9 |
Share price reference (AUD)
| Share price reference (AUD) | Value |
|---|---|
IPO price, Dec 2019 (AUD) | 2.66 |
All-time high (AUD) | 4.53 |
~Oct 2023 reference (AUD, director buy 24 Oct 2023) | 0.93 |
~Oct 2025 reference (AUD, institutional trades mid-Oct 2025) | 1.25 |
Close 25 Aug 2026 post-results (AUD) | 0.80 |
Close 15 Oct 2026 (AUD) | 0.67 |
Period return (%)
| Period return (%) | Return |
|---|---|
1-year price return to mid-Oct 2026 (%) | -46 |
3-year price return to mid-Oct 2026 (%) | -28 |
5-year price return (%, Simply Wall St, as at early 2026) | -64 |
Since IPO (%) | -75 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation (AUD Mn) | 357 | Derived |
Trailing P/E, statutory (x) | 16.8 | FY26 NPAT A$21.3m |
Trailing P/E on normalised PBT taxed at 30% (x) | 20.7 | FY26 normalised PBT A$24.7m × 0.7 |
Price / gross profit (x) | 1.54 | FY26 GP A$231.8m |
Price / revenue (x) | 0.73 | FY26 revenue A$489.4m |
Price / FCF (x) | 12.1 | FY26 FCF A$29.4m |
Price / NTA (x) | 2.8 | NTA A$0.24 per share |
EV/EBITDA (x) | Not computed | — |
EV/Sales (x, fund manager estimate, June 2026) | 0.7 | Thesis Tracker |
FY27E P/GP at guidance midpoint (x) | 1.4 | A$247.5m |
Capital return (AUD cents per share)
| Capital return (AUD cents per share) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Analyst Conclusions
Management guidance (FY27)
-
Normalised gross profit A$240m–A$255m (growth of ~3.5%–10.0% on FY26's A$231.8m).
-
EBITDA margin 28.5%–30.5% of gross profit (implied EBITDA ~A$68m–A$78m).
-
Management expects continued gross profit growth with strong financial discipline, and cites early FY27 customer wins (FY26 release).
Consensus growth expectations
Simply Wall St's community narrative (Dec 2025) assumed revenue growth of ~2.9% p.a. and net margin ~3.5% — materially more conservative than management's GP guidance, highlighting the gap between revenue and gross-profit growth as interchange pass-through changes.
Bull case
-
Operating leverage is real and continuing: EBITDA has grown every year since FY22 while gross profit grew 5%–9%; FY27 guidance implies another step-up, and FCF of ~A$29m on a ~A$357m market cap (~8% yield) is unusual for a fintech.
-
Regulatory reset favours Tyro: The surcharging ban removes the "zero-cost EFTPOS" model that undercut Tyro on price, while transparency rules favour simpler, integrated offerings; several fund managers regard the reform as a net positive.
-
Strategic value and takeover floor: Tyro has attracted interest from Potentia (up to A$1.60), Westpac, reportedly Stripe, and unnamed parties in 2025 — the current A$0.67 price is far below past bid levels, providing asymmetric upside if corporate activity resumes.
Bear case
-
Volume growth remains anaemic: TTV growth averaged ~1.3% p.a. from FY23 to FY26, and revenue growth was 0.7% in FY26; gross profit gains have depended on pricing, banking and interest income that may not repeat.
-
Margin pressure from reforms and competition: Interchange cuts, published fee benchmarks and global competitors (Stripe, Adyen, Square, Shift4/Smartpay) could force MSF reductions, compressing payments gross profit.
-
Execution and leadership risk: A new CEO (Jan 2026), new COO (Feb 2026) and a departing CFO (Sept 2026) must execute a multi-front strategy (Health, Banking, Enterprise, eCommerce, accounting software) with limited scale and R&D resources.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q1 FY27 trading update / 2026 AGM | Nov 2026 | First read on post-surcharge-ban pricing and volumes |
| CFO appointment | H2 CY2026–H1 CY2027 | Continuity of capital management |
| H1 FY27 results | Late Feb 2027 | Progress versus A$240–255m GP guidance; EBITDA margin trajectory |
| RBA foreign-card interchange cap and enhanced statements | 1 Apr 2027 | Further pricing/transparency changes |
| RBA consultation on wallets, Amex, BNPL, eCommerce platforms | 2026–2027 | Potential further regulatory change |
| Banking attach and deposit growth | Ongoing | Key GP-per-merchant driver |
| Tyro Health growth (Allied Health, Dental, vet) | Ongoing | Highest-growth vertical |
| Thriday/Tyro Accounting adoption | Ongoing | Evidence of multi-product strategy |
| Capital management (dividend/buyback initiation or M&A) | Ongoing | Use of surplus capital |
| Corporate approaches | Unpredictable | Potential premium realisation |
| FY27 results | Late Aug 2027 | Guidance delivery |
Analyst verdict
Tyro Payments has completed one of the more convincing turnarounds among ASX fintechs. Between FY22 and FY26, normalised gross profit rose from A$148.5m to A$231.8m, EBITDA from A$10.7m to A$66.9m, and statutory results swung from a A$29.6m loss to a A$21.3m profit, with free cash flow of A$29.4m in FY26. Management has met gross-profit guidance three years running, and the balance sheet is ungeared with rising tangible equity. On almost any cash-flow measure, the shares — at roughly A$0.67, a ~A$357m market capitalisation, ~12x free cash flow and ~1.5x gross profit — look inexpensive.
The market's scepticism, however, is rational rather than careless. Transaction value has barely grown since FY23, revenue is essentially flat, and much of the gross-profit progress has come from repricing, banking float and treasury income rather than share gains. The RBA's surcharging ban and interchange cuts, effective October 2026, introduce genuine uncertainty about merchant pricing, and Tyro competes against banks and global platforms with far greater scale and investment capacity. Leadership turnover — a new CEO in January 2026 and the CFO's resignation in September — adds execution risk at a pivotal moment.
On balance, the investment case rests on three questions: whether Tyro can re-accelerate core volumes (FY26's 4.4% core volume growth is encouraging), whether multi-product adoption (banking, health, accounting) lifts gross profit per merchant materially, and whether the board will either return surplus capital or engage with a credible bidder at a price closer to historical offers. The FY27 guidance (A$240–255m GP, 28.5–30.5% EBITDA margin) is a reasonable bar. We regard Tyro as an undervalued, cash-generative but low-growth niche operator, with upside skewed by strategic optionality and downside cushioned by profitability; delivery of mid-to-upper FY27 guidance alongside a CFO appointment and a capital-management decision would likely be required for a sustained re-rating.
APPENDIX: KEY SOURCES
-
Tyro FY26 results media release (tyro.com / ASX) — 25 Aug 2026 — FY26 headline results, guidance, wins, health/banking KPIs
-
Tyro 2026 Annual Report / Appendix 4E (ASX) — 25 Aug 2026 — TTV, PBT, NPAT, NTA, revenue, dividend
-
Tyro FY26 Investor Presentation (ASX) — 25 Aug 2026 — Strategy themes, A$1tn market, banking metrics
-
FY26 results call transcript (Investing.com) — 25 Aug 2026 — Core volume growth, FCF conversion, health growth
-
Appointment of Managing Director (ASX) — 25 Aug 2026 — Lee board appointment
-
Tyro H1 FY26 results release (ASX/tyro.com) — 24 Feb 2026 — H1 FY26 results
-
Tyro FY25 results release, Annual Report, presentation, transcript — 26 Aug 2025 — FY25 results and segment GP
-
2025 AGM addresses and presentation (ASX) — 26 Nov 2025 — Operating efficiency, guidance reaffirmation
-
Tyro FY24 results release and Annual Report — 26 Aug 2024 — FY24 results, FY23 restated segment GP
-
Tyro FY23 results release, Appendix 4E, presentation — Aug 2023 — FY23 results, FY22 comparatives
-
Tyro FY22 results release and presentation — 29 Aug 2022 — FY22 results
-
RBA Review of Merchant Card Payment Costs and Surcharging — Conclusions Paper — 31 Mar 2026 — Regulatory reform details
-
Capital Brief; Business News Australia; Reuters (Stockopedia); Motley Fool; Kalkine; Stockhead; IG; ShareCafe; Finovate; Listcorp; Morningstar — 2020–2026 — Event chronology, takeover history, executive changes, share price
-
Aggregators: MarketScreener, Trading Economics, StockAnalysis, Market Index, InvestSMART, Simply Wall St, HALO, IBISWorld — 2025–2026 — Flagged supplementary data (segments, employees, auditor, share prices, holders)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education | Source |
|---|---|---|---|---|---|
Nigel Lee | CEO (from 12 Jan 2026); Managing Director and director (from 31 Aug 2026) | <1 year | Global Chief Customer Officer and Head of Asia Pacific, Ingenico (led commercial strategy across 100+ countries); senior roles at DataMesh Group, American Express, First Data, MoneyGram; operating partner at APIS Partners (fintech PE); board adviser to fintech start-ups; relocated from Singapore | Reported MEng, Chemical Engineering, Imperial College London (single aggregator source) | tyro.com leadership page; Capital Brief; InvestSMART; TheOfficialBoard |
Emma Burke | CFO (resigning) | Joined Oct 2024; resignation announced 29 Sep 2026 (leaving for Built Living CFO role); acting CEO 5 Dec 2025–12 Jan 2026 | 25+ years leading finance teams in consumer goods and property | — | tyro.com; Listcorp; ShareCafe |
Andrew Chanmugam | Chief Operating Officer | Joined Feb 2026 | — | — | tyro.com |
Steve (surname not confirmed in sources) | Chief Technology Officer | Joined Aug 2024 | — | — | tyro.com |
Adriano (surname not confirmed in sources) | CEO, Tyro Health | Joined May 2021 via Medipass acquisition; leads Tyro Health since Oct 2022 | Medipass leadership | — | tyro.com |
Monica Appleby | Chief People and Communications Officer | Joined 2020; CPCO since 2021 | KPMG, Deloitte, Tabcorp (Australia and UK) | — | tyro.com |
Chief Risk Officer (name not shown in retrieved text) | CRO | Joined Mar 2019; CRO since 10 Jun 2021 | — | — | tyro.com |
Sami Wilson | General Counsel | Since c.2017 | — | — | MarketScreener |
Jairan Amigh | Special Counsel & Company Secretary | Since 2020 | — | — | MarketScreener; AGM transcript |
Michael Nuciforo | Thriday founder/CEO; joined Tyro | From Jan 2026 | Founder, Thriday | — | Finovate |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Appointed | Background / other roles | Age (if disclosed) | Source |
|---|---|---|---|---|---|
Fiona Pak-Poy | Independent Non-Executive Chair | Director Sep 2019; Chair from Feb/Mar 2023 | 30+ years in technology, finance, government and NFP; director of HMC Capital (from Nov 2024); prior chair roles in private companies | — | InvestSMART; MarketScreener; Business News Australia |
Nigel Lee | CEO & Managing Director | 31 Aug 2026 | See above | — | ASX release 25 Aug 2026 |
Paul Rickard | Independent Non-Executive Director | 2009 (longest-serving) | Not detailed in sources reviewed | — | InvestSMART |
Aliza Knox | Independent Non-Executive Director | 21 Apr 2021 | Not detailed in sources reviewed (ex-tech executive per prior knowledge) | ~65 (aggregator) | MarketScreener |
Claire Hatton | Independent Non-Executive Director | 5 Jan 2022 | Seven years on Google Australia's commercial leadership team; NED roles; co-founder Full Potential Labs | ~54 (aggregator) | FNN, Jan 2022 |
Shefali Roy | Independent Non-Executive Director | 5 Jan 2022 | Former COO and CCO of TrueLayer; senior roles at Stripe, Apple, Christie's, Goldman Sachs; teaches at Oxford Saïd | — | FNN, Jan 2022 |
Steven Holmes | Independent Non-Executive Director | 3 Jun 2025 | Not detailed in sources reviewed | ~46 (aggregator) | MarketScreener; AGM transcript |
“—” = not publicly disclosed.
Directors' Remuneration
| Item | Detail | Source |
|---|---|---|
Nigel Lee fixed annual remuneration | A$830,000, plus STI and LTI subject to performance; no change on appointment as MD | ASX release 5 Nov 2025 (via InvestSMART); ASX release 25 Aug 2026 |
Jon Davey FY26 pro-rated STI | A$169,000 (67% of on-target) | ShareCafe, 26 Nov 2025 |
Jon Davey equity treatment | 267,857 of 297,619 FY21 Medipass service rights accelerated/pro-rated; FY23 LTI: 586,548 vested, 695,503 lapsed; >2.5m FY24/FY25 LTI rights cancelled | ShareCafe |
Major Shareholders
| Holder | Stake / latest movement | Status | Source |
|---|---|---|---|
Spheria Asset Management | Bought 28.3m shares Aug 2025; further trades Sept 2025 | — | Simply Wall St insider log |
Macquarie Group entities | Increased stake Oct and Dec 2025 | — | Simply Wall St; MarketScreener (23 Dec 2025) |
Pinnacle Investment Management | Purchases June–July 2025 | Substantial holder at the time | Simply Wall St |
The Vanguard Group | Increased Aug 2025 | Substantial holder at the time | Simply Wall St |
Aware Super | Bought July 2025; sold ~0.9m Nov 2025 | Movement disclosed | Simply Wall St |
Regal Partners | Ceased to be substantial holder 22 Jul 2026 | Exited | Kalkine |
Grok Ventures (Mike Cannon-Brookes) | Significant holder in 2022 (voting deed with Potentia at A$1.27) | — | IG (Dec 2022) |
Top-10 list with exact % | Not publicly verified in this research — refer FY26 Annual Report shareholder information section | — | — |
Competitive Landscape
Key Competitors
| Competitor | Segment(s) competing | Description | Relative positioning vs Tyro |
|---|---|---|---|
Commonwealth Bank (CBA) | Acquiring, SME banking | Largest Australian merchant acquirer (incl. Smart terminals, Square-like products) | Far larger; bundles lending/banking; Tyro competes on integration/service |
Westpac | Acquiring, SME banking | Big-four acquirer; explored buying Tyro in 2022 | Larger; less vertical depth |
NAB | Acquiring, health (HICAPS), SME banking | Big-four; owns HICAPS, the incumbent in health claiming | Direct competitor to Tyro Health |
ANZ | Acquiring, SME banking | Big-four; Worldline JV for acquiring | Larger |
Block (Square) | SME acquiring, software | Global; strong in micro-merchants and POS software | Larger, software-led; flat-rate pricing |
Stripe | eCommerce, enterprise, embedded | Global online leader; reported interest in Tyro (2025) | Dominant online; weaker in-store health |
Adyen | Enterprise omnichannel | Global unified-commerce acquirer | Dominant in large enterprise |
Zeller | SME acquiring + business accounts | Australian fintech with payments + banking-style accounts | Closest like-for-like challenger |
Smartpay (now Shift4) | SME EFTPOS (AU/NZ) | Zero-cost EFTPOS surcharging model; acquired by Shift4 2025 | Direct SME competitor; surcharge ban affects its model |
Windcave | Unattended, hospitality, eCommerce | ANZ-origin gateway/acquiring tech | Niche overlap |
Fiserv/First Data, Global Payments, Worldline | Acquiring/processing | Global processors active in AU | Partners/competitors |
Lightspeed, Square, Toast-type POS-embedded payments | POS-embedded payments | POS vendors internalising payments | Threat to integration moat |
Peer Comparison FY2026
| Metric | Tyro (FY26, AUD) | Block (FY2024, USD) | Adyen (FY2024, EUR) |
|---|---|---|---|
Revenue / net revenue | A$489.4m revenue | — | — |
Growth | GP +5.3% | — | — |
Margin | EBITDA/GP 28.9% | Not comparable basis | — |
R&D intensity | — | High (tech-led) | High |
Market share in Australia | Not disclosed (5th-largest acquirer by terminals per older boilerplate) | — | — |
“—” = not publicly disclosed.



